Publications hub
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
We’re still confirming the best location for some of our content. Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Regulatory compliance (8)
- (-) COVID-19 vaccines (7)
- (-) Alert/Advisory (3)
- Advisory bodies and committees (364)
- Scheduling (national classification system) (157)
- Prescription medicines (36)
- Advertising (25)
- In Vitro Diagnostic medical devices (IVDs) (24)
- Medicine safety (23)
- Therapeutic goods regulation (20)
- Medical devices safety (14)
- Manufacturing (11)
- Safety (11)
- Non-prescription medicines (10)
- Complementary medicines (9)
- Over the counter (OTC) medicines (8)
- Listed medicines (7)
- Registered complementary medicines (7)
- COVID-19 (6)
- Medicinal cannabis hub (6)
- Assessed listed medicines (5)
- Shortages (4)
- Clinical trials (3)
- Fees and payments (3)
- Legislation (3)
- Compliance and enforcement hub (2)
- Import and export (2)
- Sunscreens (2)
- Artificial Intelligence (AI) (1)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biological medicines (1)
- Breast implant hub (1)
- Cosmetics (1)
- Disinfectants/Sterilants (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Pharmacovigilance (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
17 result(s) found, displaying 1 to 17
-
PublicationsClarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
PublicationsThis plan outlines our compliance and education priorities for 2024-2025.
-
Summary report of residual DNA and endotoxin on COVID-19 mRNA vaccines conducted by TGA Laboratories
TGA laboratory testing reportsThe TGA has conducted a comprehensive evaluation of the residual DNA and endotoxin levels in the two mRNA vaccines supplied in Australia - Comirnaty (Pfizer) and Spikevax (Moderna). -
PublicationsThis fact sheet is for healthcare practitioners to help understand the rules surrounding importation of cosmetic injectables.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 45, held on 4 October 2023.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 46, held on 29 November 2023.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2021-22
-
TGA laboratory testing reportsIn consultation with the TGA, Edgewell has taken a precautionary approach and commenced a recall of all batches of these three products from the Australian market.
-
PublicationsUpdates to the ICMRA landing page detailing ICMRA's projects and their role during the COVID-19 pandemic.
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
TGA laboratory testing reportsThis testing project was designed to assess compliance with the new Standard
-
TGA laboratory testing reportsTGA Laboratories has released a report detailing testing of alkyl nitrite products